Literature DB >> 29381093

The Effects of Inflammation on Alpha 1 Antitrypsin Levels in a National Screening Cohort.

Christopher L Sanders1, Amy Ponte1, Friedrich Kueppers2.   

Abstract

Alpha 1 Antitrypsin (AAT) is a highly polymorphic serum protein. Several genetic variants are associated with varying degrees of decreased serum levels; however, these levels can rise in response to infection, inflammation, injury and estrogen levels. Although the effect of inflammation is well established, it has never been studied quantitatively with respect to specific genotypes in a large representative sample. Using data from a national AAT deficiency-targeted screening cohort, we evaluated AAT levels of patients with normal and deficiency genotypes in response to inflammation, indicated by elevated serum C-reactive protein (CRP). Additionally, we utilized a regression analysis to adjust for the effect of inflammation for each genotype. Across all stratified genotype groups, increased AAT levels were observed in patients with CRP ≥5 mg/L. Different AAT phenotypes reacted differently in the acute phase; M showed a strong response and Z a reduced reaction. Nevertheless, we discovered that inflammation significantly masked clinically relevant base AAT levels in some PI*MZ individuals; approximately a quarter of PI*MZ samples showed signs of inflammation. Median AAT levels (mg/dL) in the presence of inflammation are given for several genotypes; numbers in parentheses are levels from the cohort without inflammation/adjusted levels from the cohort with inflammation using the newly devised algorithm: PI*MM: 162 (142/140); PI*MS: 136 (117/115); PI*MZ: 104 (85/89); PI*MF: 161 (132/141); PI*SS: 115 (96/91); PI*SZ: 66 (54/50). We conclude that simultaneous determinations of CRP and AAT levels, and genotyping are clinically valuable in defining AAT variants and that the effect of inflammation can be adjusted for.

Entities:  

Keywords:  Alpha 1 Antitrypsin deficiency; C-reactive protein; inflammation; screening; testing

Mesh:

Substances:

Year:  2018        PMID: 29381093     DOI: 10.1080/15412555.2017.1401600

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  15 in total

1.  Alpha-1 Antitrypsin Substitution for Extrapulmonary Conditions in Alpha-1 Antitrypsin Deficient Patients.

Authors:  Boris M Baranovski; Ronen Schuster; Omer Nisim; Ido Brami; Yotam Lior; Eli C Lewis
Journal:  Chronic Obstr Pulm Dis       Date:  2018-09-19

2.  IntraIndividual Variability in Serum Alpha-1 Antitrypsin Levels.

Authors:  Annie Haillot; Andrée-Anne Pelland; Yohan Bossé; Tomás P Carroll; François Maltais; Ronald J Dandurand
Journal:  Chronic Obstr Pulm Dis       Date:  2021-10-28

3.  Low Prevalence of Mild Alpha-1-Antitrypsin Deficiency in Hospitalized COVID-19-Patients.

Authors:  David Nygren; Ulrica Mölstad; Hans Thulesius; Magnus Hillman; Lars Mikael Broman; Hanan Tanash; Mona Landin-Olsson; Magnus Rasmussen; Maria Thunander
Journal:  Int J Gen Med       Date:  2022-06-28

Review 4.  Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype.

Authors:  Gerard N McElvaney; Robert A Sandhaus; Marc Miravitlles; Gerard M Turino; Niels Seersholm; Marion Wencker; Robert A Stockley
Journal:  Eur Respir J       Date:  2020-06-18       Impact factor: 16.671

Review 5.  New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency.

Authors:  Joanna Chorostowska-Wynimko; Miriam Barrecheguren; Ilaria Ferrarotti; Timm Greulich; Robert A Sandhaus; Michael Campos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-02-12

6.  Clinical presentations of four patients with rare Alpha 1 Antitrypsin variants identified in a single US center.

Authors:  Friedrich Kueppers
Journal:  Respir Med Case Rep       Date:  2021-01-20

Review 7.  Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis.

Authors:  Igor Barjaktarevic; Marc Miravitlles
Journal:  BMC Pulm Med       Date:  2021-03-23       Impact factor: 3.317

Review 8.  Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives.

Authors:  Mark Quinn; Paul Ellis; Anita Pye; Alice M Turner
Journal:  Ther Clin Risk Manag       Date:  2020-12-16       Impact factor: 2.423

9.  Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory.

Authors:  Irene Belmonte; Alexa Nuñez; Miriam Barrecheguren; Cristina Esquinas; Mònica Pons; Rosa M López-Martínez; Gerard Ruiz; Albert Blanco-Grau; Roser Ferrer; Joan Genescà; Marc Miravitlles; Francisco Rodríguez-Frías
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-10-07

10.  The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes.

Authors:  Tomoko Nakanishi; Vincenzo Forgetta; Tomohiro Handa; Toyohiro Hirai; Vincent Mooser; G Mark Lathrop; William O C M Cookson; J Brent Richards
Journal:  Eur Respir J       Date:  2020-12-10       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.